期刊文献+

阿司匹林、华法林和噻吩吡啶类药物在急性冠状动脉综合征中的应用

Aspirin, warfarin and a thienopyridine for acute coronary syndromes
下载PDF
导出
摘要 Background: Although clopidogrel and aspirin(dual therapy, DT) are used for acute coronary syndrome(ACS), sometimes treatment with warfarin(triple therapy, TT) is required. Aim: To determine the incidence, complications, and outcomes of TT. Methods: We analyzed Israeli surveys of ACS from 2000 to 2004. Results: In these surveys, 5,706(96% ) were discharged alive from hospital. Post- ACS TT and DT were 76 patients(1.3% ) and 2,661 patients(46.7% ), respectively. The TT group was older with more prior cardiac disease. During hospitalization, the TT patients received more intravenous anticoagulant and antithrombotic agents, and had more heart failure, arrhythmias, ischemia, and major bleeding(2.6 vs. 0.6% , p=0.03). There were no differences in adjusted 30- day and 6- month mortality between the 2 groups. Conclusion: TT is feasible among ACS patients who require concomitant warfarin treatment. Background: Although clopidogrel and aspirin(dual therapy, DT) are used for acute coronary syndrome(ACS), sometimes treatment with warfarin(triple therapy, TT) is required. Aim: To determine the incidence, complications, and outcomes of TT. Methods: We analyzed Israeli surveys of ACS from 2000 to 2004. Results: In these surveys, 5, 706(96% ) were discharged alive from hospital. Post-ACS TT and DT were 76 patients( 1.3% ) and 2, 661 patients(46. 7% ), respectively. The TT group was older with more prior cardiac disease. During hospitalization, the TT patients received more intravenous anticoagulant and antithrombotic agents, and had more heart failure, arrhythmias, ischemia, and major bleeding(2.6 vs. 0. 6%, p =0. 03) . There were no differences in adjusted 30-day and 6-month mortality between the 2 groups. Conclusion: Tr is feasible among ACS patients who require concomitant warfarin treatment.
机构地区 Cardiology Department
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部